Tolvaptan is a prescription medication that blocks a hormone in your kidneys responsible for retaining water. By doing so, it causes your body to excrete large amounts of dilute urine without losing essential electrolytes like sodium and potassium. It is approved to treat two distinct conditions: dangerously low sodium levels in the blood (hyponatremia) and autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow on the kidneys.
How Tolvaptan Works in the Kidneys
Your body produces a hormone called vasopressin (also known as antidiuretic hormone) that tells your kidneys to hold on to water. Vasopressin does this by binding to V2 receptors on cells in the kidney’s collecting ducts. Once activated, these receptors trigger a chain of signals that ultimately moves water channels called aquaporin-2 to the cell surface, allowing water to be reabsorbed back into the bloodstream.
Tolvaptan inserts itself deeply into the binding pocket of the V2 receptor, physically blocking vasopressin from attaching. With that signal interrupted, aquaporin-2 channels never reach the cell surface. The result is that water passes straight through into urine instead of being pulled back into the body. This “water-only” diuretic effect is sometimes called aquaresis, distinguishing it from traditional diuretics that also flush out sodium and potassium.
Conditions It Treats
Under the brand name Samsca, tolvaptan is approved for clinically significant hyponatremia, specifically the hypervolemic and euvolemic types. These occur when the body either retains too much water (diluting sodium) or produces vasopressin inappropriately, as in the syndrome of inappropriate antidiuretic hormone (SIADH) or certain cases of heart failure. It is indicated when serum sodium falls below 125 mEq/L, or when levels are somewhat higher but the patient has symptoms that haven’t responded to fluid restriction alone. It is not appropriate for hypovolemic hyponatremia, where low sodium results from actual fluid loss, or for situations where sodium needs to be raised urgently to prevent neurological damage.
Under the brand name Jynarque, tolvaptan is approved for ADPKD. In polycystic kidney disease, vasopressin signaling drives cyst growth. Blocking V2 receptors slows the expansion of kidney cysts and helps preserve kidney function over time. The two pivotal trials, TEMPO 3:4 and REPRISE, showed that long-term tolvaptan use slowed the rate of kidney function decline in adults at risk of rapidly progressing disease.
What Taking Tolvaptan Feels Like
The most noticeable effects are directly tied to how the drug works. In the TEMPO 3:4 trial for ADPKD, about 70% of people taking tolvaptan reported significantly increased urination, compared to 28% on placebo. Nearly 64% experienced pronounced thirst, versus 23% on placebo. Dry mouth affected 16% of tolvaptan users. These aren’t really side effects in the traditional sense; they’re the drug doing its job. Your kidneys are releasing far more water than usual, and your body signals you to drink more to compensate.
For many people, the frequent urination and thirst are most intense in the first days and weeks. Guidelines from KDIGO, the international kidney disease organization, note that polyuria decreases to some extent over time and becomes more tolerable. Still, the aquaretic effects were the single most common reason people stopped taking the drug. In clinical trials, about 6.6% of tolvaptan users discontinued specifically because of frequent urination, urgent urination, or nighttime urination, compared to just 0.2% on placebo. Overall, 15.4% of tolvaptan users stopped treatment due to adverse events of any kind.
Liver Safety and the 30-Day Limit
Tolvaptan can cause serious liver injury. For this reason, when used for hyponatremia (Samsca), treatment is limited to a maximum of 30 days. The FDA label states this cap explicitly to minimize liver risk. Patients typically have liver enzymes and bilirubin checked before starting, two weeks in, and then every one to two months if treatment continues.
For ADPKD (Jynarque), long-term use is necessary to slow disease progression, so the 30-day cap does not apply. However, regular liver monitoring is mandatory, and treatment is stopped if liver enzyme levels rise significantly. Patients enrolled in the ADPKD program must participate in a risk management program that includes routine blood testing.
Dosing for Each Condition
The dosing approach differs between the two uses. For ADPKD, the medication is taken as a split dose: a larger dose in the morning and a smaller dose about eight hours later. The starting regimen is typically 45 mg in the morning followed by 15 mg in the afternoon, then titrated up to 60 mg/30 mg, and potentially to a maximum of 90 mg/30 mg depending on how well you tolerate the effects. If the thirst or urination becomes unmanageable, the dose can be stepped back down.
For hyponatremia, dosing starts lower and is adjusted based on how quickly sodium levels respond. During the first 24 hours, sodium levels are checked roughly every six hours to make sure they don’t rise too fast. Overly rapid correction of sodium can cause a dangerous neurological condition, so close monitoring during initiation is essential, which is why treatment is typically started in a hospital setting.
Hydration and Practical Tips
Because tolvaptan dramatically increases urine output, you need to drink enough water to keep up. Dehydration is a real risk if you don’t match your fluid losses. You should drink whenever you feel thirsty, and guidelines recommend not trying to fight the thirst or restrict fluids while on this medication.
There are situations where you should skip a dose entirely. If you’re ill with vomiting or diarrhea, exercising heavily in hot weather, traveling without reliable access to water, or otherwise at risk for dehydration, holding the medication is the safer choice. Kidney disease guidelines recommend that everyone on tolvaptan for ADPKD have a “sick day plan” that includes temporarily pausing the drug whenever there’s a risk of volume depletion.
Drug and Food Interactions
Tolvaptan is broken down in the liver by a specific enzyme system called CYP3A. Anything that strongly inhibits this enzyme can cause tolvaptan to build up to dangerously high levels in the body. Strong inhibitors of this pathway, including certain antifungal medications, some antibiotics like clarithromycin, and several HIV medications, are contraindicated with tolvaptan entirely. One common antifungal raised tolvaptan blood levels fivefold.
Moderate inhibitors of the same enzyme system, including certain calcium channel blockers (diltiazem, verapamil) and the antibiotic erythromycin, should generally be avoided as well because they can substantially increase tolvaptan exposure. On the flip side, drugs that speed up this enzyme system, such as certain seizure medications and the herbal supplement St. John’s Wort, can reduce tolvaptan levels enough to make it ineffective.
Grapefruit juice is a well-known inhibitor of this enzyme pathway. Drinking it while on tolvaptan nearly doubles the drug’s blood levels. If you’re prescribed tolvaptan, avoiding grapefruit and grapefruit juice is a straightforward way to prevent unpredictable dosing.